Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 12/2019

01-12-2019 | Obesity | Original Contributions

Propofol Sedation for Intragastric Balloon Removal: Looking for the Optimal Body Weight Descriptor

Authors: Georgia Tsaousi, Barbara Fyntanidou, George Stavrou, Pyrros Papakostas, Katerina Kotzampassi, Vasilios Grosomanidis

Published in: Obesity Surgery | Issue 12/2019

Login to get access

Abstract

Aim

Sedation is considered as a prerequisite for the safe and effective conclusion of Bioenterics Intragastric Balloon (BIB) removal (our aim was to ascertain the most appropriate body size scalars for propofol dosing and assess the efficacy and safety of a sedative approach involving the infusion of propofol for BIB removal.

Method

Retrospective analysis of prospectively collected data of 414 adults scheduled to undergo BIB removal. Our primary end-point was to delineate the relationship between propofol dosing and body size descriptors namely body mass index, total body weight, ideal body weight, lean body weight (LBW) and normalized LBW. Sedative efficacy of this practice, anesthesia or procedural-related adverse events and patients’ satisfaction level served as secondary outcome parameters.

Results

Propofol dose (mg/kg/min) was positively related to all body weight descriptors in an important manner (p < 0.001). Among them, LBW was singled out as the body size descriptor to best capture the appropriate needs of propofol (R2 = 0.432; p = 0.000). Hypoxemia, hemodynamic compromise, gastroesophageal reflux or moderate movement occurred rarely; all of them were readily reversed. The majority of participants had no recollection of the noxious phase of the procedure or declared at least adequately satisfied from the experience (84% and 95%, respectively).

Conclusion

LBW could serve as relatively more accurate dosing scalar compared to actual or ideal body weight descriptors, in obese individuals undergoing BIB removal under propofol sedation. The conscious/deep sedation based on propofol infusion emerges as a feasible and efficacious sedative approach for this procedure.
Literature
1.
De Baerdemaeker L, Margarson M. Best anaesthetic drug strategy for morbidly obese patients. Curr Opin Anaesthesiol. 2016;29:119–28.PubMed
2.
Neto MG, Silva LB, Grecco E, et al. Brazilian Intragastric balloon consensus statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis. 2018;14(2):151–9.PubMed
3.
Messina T, Genco A, Favaro R, et al. Intragastric balloon positioning and removal: sedation or general anesthesia? Surg Endosc. 2011;25(12):3811–4.PubMed
4.
Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. 2012;22:896–903.PubMed
5.
Kotzampassi K, Shrewsbury AD, Papakostas P, et al. Looking into the profile of those who succeed in losing weight with an intragastric balloon. J Laparoendosc Adv Surg Tech A. 2014;24:295–301.PubMed
6.
Sudré ECM, de Batista PR, Castiglia YMM. Longer immediate recovery time after anesthesia increases risk of respiratory complications after laparotomy for bariatric surgery: a randomized clinical trial and a cohort study. Obes Surg. 2015;25:2205–12.PubMed
7.
Cortínez LI, Anderson BJ. Advances in pharmacokinetic modeling: target controlled infusions in the obese. Curr Opin Anaesthesiol. 2018;31:415–22.PubMed
8.
Cortinez LI, Anderson BJ, Penna A, et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth. 2010;105:448–56.PubMed
9.
Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58:119–33.PubMedPubMedCentral
10.
Horgan GW, Stubbs J. Predicting basal metabolic rate in the obese is difficult. Eur J Clin Nutr. 2003;57:335–40.PubMed
11.
Wong C, Marwick TH. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med. 2007;4:436–43.PubMed
12.
Subramani Y, Riad W, Chung F, et al. Optimal propofol induction dose in morbidly obese patients: a randomized controlled trial comparing the bispectral index and lean body weight scalar. Can J Anaesth. 2017;64:471–9.PubMed
13.
Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051–65.PubMed
14.
Lemmens HJ, Brodsky JB, Bernstein DP. Estimating ideal body weight: a new formula. Obes Surg. 2005;15:1082–3.PubMed
15.
Callaghan LC, Walker JD, Williams DJ. Nomograms for calculating drug doses in obese adults. Anaesthesia. 2016;71:977–8.PubMed
16.
Hicks C, Trickett A, Kwan YL, et al. The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation. Ann Hematol. 2012;91:1795–801.PubMed
17.
Shin S, Park CH, Kim HJ, et al. Patient satisfaction after endoscopic submucosal dissection under propofol-based sedation: a small premedication makes all the difference. Surg Endosc. 2017;31(6):2636–44.PubMed
18.
de Graaff JC, Bijker JB, Kappen TH, et al. Incidence of intraoperative hypoxemia in children in relation to age. Anesth Analg. 2013;117:169–75.PubMed
19.
Liu Y, Pian-Smith MC, Leffert LR, et al. Continuous measurement of cardiac output with the electrical velocimetry method in patients under spinal anesthesia for cesarean delivery. J Clin Monit Comput. 2015;29:627–34.PubMed
20.
Brice DD, Hetherington RR, Utting JE. A simple study of awareness and dreaming during anaesthesia. Br J Anaesth. 1970;42:535–42.PubMed
21.
Likert R. A technique for the measurement of attitudes. Arch Psychol. 1932;22:1–55.
22.
Pandit JJ, Cook TM, Jonker WR, et al. A national survey of anaesthetists (NAP5 baseline) to estimate an annual incidence of accidental awareness during general anaesthesia in the UK. Anaesthesia. 2013;68:343–53.PubMed
23.
Riphaus A, Wehrmann T, Weber B, et al. S3 guideline: sedation for gastrointestinal endoscopy 2008. Endoscopy. 2009;41:787–815.
24.
Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg. 2011;113:57–62.PubMed
25.
Sasaki T, Tanabe S, Azuma M, et al. Propofol sedation with bispectral index monitoring is useful for endoscopic submucosal dissection: a randomized prospective phase II clinical trial. Endoscopy. 2012;44:584–9.PubMed
26.
Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 2010;105(Suppl 1):i16–23.PubMed
27.
Dong D, Peng X, Liu J, et al. Morbid obesity alters both pharmacokinetics and pharmacodynamics of propofol: dosing recommendation for anesthesia induction. Drug Metab Dispos. 2016;44:1579–83.PubMed
28.
Martin JH, Saleem M, Looke D. Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology. Br J Clin Pharmacol. 2012;73(5):685–90.PubMed
29.
Diepstraten J, Chidambaran V, Sadhasivam S. Blussé van oud-Alblas HJ, Inge T, et al. an integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst Pharmacol. 2013;2:e73.PubMedPubMedCentral
30.
Leykin Y, Miotto L, Pellis T. Pharmacokinetic considerations in the obese. Best Pract Res Clin Anaesthesiol. 2011;25:27–36.PubMed
31.
Friesen JH. Estimating the induction dose of propofol in morbid obesity: striking a happy medium. Br J Anaesth. 2016;116(5):730–1.PubMed
32.
Eleveld DJ, Proost JH, Cortinez LI, et al. A general purpose pharmacokinetic model for propofol. Anesth Analg. 2014;118:1221–37.PubMed
33.
Eleveld DJ, Proost JH, Vereecke H, et al. An allometric model of remifentanil pharmacokinetics and pharmacodynamics. Anesthesiology. 2017;126:1005–18.PubMed
34.
Badaoui R, Cabaret A, Alami Y, et al. Reversal of neuromuscular blockade by sugammadex in laparoscopic bariatric surgery: in support of dose reduction. Anaesth Crit Care Pain Med. 2016;35:25–9.PubMed
35.
Lemmens HJ. Perioperative pharmacology in morbid obesity. Curr Opin Anaesthesiol. 2010;23:485–91.PubMed
36.
Scherrer PD, Mallory MM, Cravero JP, et al. The impact of obesity on pediatric procedural sedation-related outcomes: results from the pediatric sedation research consortium. Paediatr Anaesth. 2015;25:689–97.PubMed
37.
Meyhoff CS, Henneberg SW, Jorgensen BG, et al. Depth of anaesthesia monitoring in obese patients: a randomized study of propofol-remifentanil. Acta Anaesthesiol Scand. 2009;53:369–75.PubMed
38.
Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82:505–8.PubMed
39.
Liu FL, Cherng YG, Chen SY, et al. Postoperative recovery after anesthesia in morbidly obese patients: a systematic review and meta-analysis of randomized controlled trials. Can J Anaesth. 2015;62:907–17.PubMed
40.
Leslie K, Clavisi O, Hargrove J. Target-controlled infusion versus manually-controlled infusion of propofol for general anaesthesia or sedation in adults. Cochrane Database Syst Rev. 2008;3:CD006059.
41.
Laosuwan S, Pongruekdee S, Thaharavanich R. Comparison of effective-site target controlled infusion and manually controlled infusion of propofol for sedation during spinal anesthesia. J Med Assoc Thail. 2011;94:965–71.
Metadata
Title
Propofol Sedation for Intragastric Balloon Removal: Looking for the Optimal Body Weight Descriptor
Authors
Georgia Tsaousi
Barbara Fyntanidou
George Stavrou
Pyrros Papakostas
Katerina Kotzampassi
Vasilios Grosomanidis
Publication date
01-12-2019
Publisher
Springer US
Published in
Obesity Surgery / Issue 12/2019
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-019-04075-0

Other articles of this Issue 12/2019

Obesity Surgery 12/2019 Go to the issue

Original Contributions

One Anastomosis Gastric Bypass/Minigastric Bypass in Patients with BMI < 35 kg/m2 and Type 2 Diabetes Mellitus: Preliminary Report

Original Contributions

Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Attenuate Pro-inflammatory Small Intestinal Cytokine Signatures

Original Contributions

Increase in Protein Intake After 3 Months of RYGB Is an Independent Predictor for the Remission of Obesity in the First Year of Surgery

Original Contributions

Non-responders After Gastric Bypass Surgery for Morbid Obesity: Peptide Hormones and Glucose Homeostasis

Original Contributions

Metabolic Features of Individuals with Obesity Referred for Bariatric and Metabolic Surgery: a Cohort Study

Original Contributions

Cost-Utility of Laparoscopic Roux-en-Y Gastric Bypass in Chinese Patients with Type 2 Diabetes and Obesity with a BMI ≥ 27.5 kg/m2: a Multi-Center Study with a 4-Year Follow-Up of Surgical Cohort